The company further disclosed that its chief science officer, Dr. Richard Tullis, has presented the clinical data underlying the article at the 12th International Conference on Dialysis.

Aethlon Medical claims that the human studies have documented the ability of Hemopurifier to reduce viral load in patients infected with Hepatitis-C virus (HCV) and the Human Immunodeficiency Virus (HIV). Its primary clinical and commercialization focus is to establish the Hemopurifier as an adjunct therapy to enhance and prolong the benefit of traditional infectious disease drug regimens.

The Hemopurifier is also a broad-spectrum treatment candidate against drug resistant bioterror and pandemic threats. The company said that third party research institutes have verified the capability of the device to capture Dengue hemorrhagic virus, Ebola hemorrhagic virus, Lassa hemorrhagic virus, West Nile virus, H5N1 Avian influenza virus, 2009 H1N1 influenza virus, the reconstructed Spanish Flu of 1918 virus, and Monkeypox virus, which serves as a model for human Smallpox infection.